e5c23a09-dd5f-4eda-8eca-f4aea9b71c20
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 61.5797399041752
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- INTERFERON_GAMMA_RESPONSE+0.550
- ALLOGRAFT_REJECTION+0.520
- IL6_JAK_STAT3_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.250
- MYC_TARGETS_V2+0.230
- KRAS_SIGNALING_DN+0.220
- PANCREAS_BETA_CELLS+0.220
- TNFA_SIGNALING_VIA_NFKB+0.220
- IL2_STAT5_SIGNALING+0.190
Top 10 suppressed
- ANGIOGENESIS-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- PROTEIN_SECRETION-0.400
- UV_RESPONSE_DN-0.360
- GLYCOLYSIS-0.350
- ANDROGEN_RESPONSE-0.340
- NOTCH_SIGNALING-0.320
- MTORC1_SIGNALING-0.300
- HEDGEHOG_SIGNALING-0.270
- OXIDATIVE_PHOSPHORYLATION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR9879287 | — | cohortA1 | 0.886 |
| 2 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.870 |
| 3 | TCGA-S3-AA17-01A-11R-A41B-07 | — | D | 0.854 |
| 4 | SRR25617828 | — | D | 0.845 |
| 5 | TCGA-GM-A2DO-01A-11R-A18M-07 | — | D | 0.840 |
| 6 | s0122145 | — | — | 0.837 |
| 7 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.820 |
| 8 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.804 |
| 9 | SRR2016954 | — | — | 0.803 |
| 10 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |